Jeff Zekauskas

Tate attributed elevated SAR to one-time Transform to Outperform costs and higher performance-based comp, and said self-help will bring the line down in H2.

Carter said export price reflects real demand, China restricting petchem feedstock so prices expected to rise. Tate said cash conversion rate to steadily improve quarter over quarter. Sadara cash commitments approximately $100M/year from 2026-2038.

Tate cited $500M cost savings closeout, $500M Transform EBITDA, $100M+ growth investments, $1.2B NOVA proceeds, and $500M working capital release for 2026.

Fitterling said JV is on the table, cited K-Global precedent on Texas-9. Alberta still a delay not cancellation; cost position and ethane advantage over decades makes it valuable. Carter said PE demand stable, Poly-7 sold out.

Fitterling said will revisit toward end of year. Long-term PE growth still needs new capacity. Tate confirmed working capital expected to improve in H2 vs H1.

Fitterling said no charge expected for Linde contract given delay length. Tate explained corporate segment seasonality and Q1 credits, guided $320M full year. Cash flow similar to Q1 pattern in Q2.

Fitterling differentiated Alberta investment as zero-emissions product with customer offtake, acknowledged European contraction is likely. Tate addressed cash flow deterioration from intentional inventory build.

Vanacker said MoReTec 1 (Wesseling) is on track for end-2027 start-up with most capacity presold; Ledet cited ongoing syngas reliability issues at La Porte affecting acid and VAM.

Kim explained China has multiple pricing buffers: 4-6 months crude inventory bought at pre-war discount of $60, coal-to-olefins setting the price floor (coal price stable like US ethane), and integrated refinery-to-PE chains still processing cheap crude. China depleting inventory to sell into Southeast Asia but not competing with LYB in NA or Europe. Peter added anti-involution focus on replacement of old assets with target dates of 2028-2029.

Peter highlighted 95% cash conversion in 2025, consistently above 90% since 2022. Trade working capital at 12-13% of revenue with no factoring. Agustin confirmed moderate working capital rebuild expected in 2026 but already factored into updated $1.3B cumulative CIP target. Peter hinted team will try to overdeliver the $500M 2026 target as they did in 2025.

Peter listed uncaptured growth from past investments: Hyperzone ($170M/yr mid-cycle), acetyls debottleneck ($75M), MoReTec-1 ($25M+), PO/TBA capacity creep ($50M on top of $450M), productivity improvements. VEP in-period contribution ~$700M vs $1.15B run rate target, leaving $450M upside. Agustin noted Q4 payables likely $40-50M lower but expects ~$1B working capital release in Q4.

Agustin explained Q1 negative cash flow driven by working capital build and Hurricane Beryl tax payments. Q2 saw $930M swing with $359M positive CFO and $117M working capital release. Noted H2 is typically much stronger for cash conversion (167% in H2 2024, 280%+ in Q4 2024 alone). Still targeting 80% full-year cash conversion.

Peter noted five remaining assets incurred $500M fixed costs in 2024. Without them, portfolio would be highly focused. Shared transformation would lift mid-cycle EBITDA margins from 18% to above 21%. Avoided giving a specific European EBITDA target.

Peter and Michael both expressed confidence in continuing dividend growth, citing strong cash conversion and disciplined CapEx. Noted the decision is in May by the Board but signaled optimism.

Petz confirmed closures were profitability-threshold driven and one-off; Meisenzahl said PCG prices more surgically by business unit and region.

Ben confirmed architectural pricing was primarily January. Jim clarified 50% propylene figure is a forecast, not current, and SHW buys derivatives not raw propylene, with time lag before P&L impact.

Ben attributed Q4 softness to tough comp (high single digit prior year); Heidi pointed to Kelly-Moore share gains now lapping.

Al pointed to the October 2024 dip to ~6% as a reference; Heidi added that affordability is the biggest impact beyond rates.

Heidi framed the opportunity as decades of differentiated strategy meeting macro turbulence and competitive choppiness; Jim explained Consumer Brands store decrease in Brazil as a channel shift to dedicated dealers.

Heidi pointed to HVAC, garage doors, window frames as top homebuilder tariff concerns; Al said household formations over 1.25M keep life moving and sub-6.5% rates would unlock pent-up demand.

Al said cold is expected in Q1 and they remain within guidance. On Consumer Brands Q4 margin narrowing, he explained Q1-Q3 benefited from fixed-cost absorption true-ups between GSC and other segments that annualized in Q4; Q4 improvement was cost control offset by lower gross profit dollars.

Norris said seven petalite mines continue operating while awaiting permits. CATL's large facility remains offline. Chinese government environmental regulations and permitting tightening had some influence. About 30,000-50,000 tons came offline but could return in 2026, which ALB has modeled.

Norris cited soft demand from oil and gas and elastomers markets, plus lithium specialties pricing compression as long-term contracts set at peak prices roll off. Pharma and semiconductors are performing well as partial offsets.

Masters said no plans to restart idled capacity in 2025 or 2026, noting restart timing would extend beyond the forecast period.

Masters confirmed current pricing around $10 in China but full-year average remains approximately $9-$9.50.

Sheorey confirmed all JV partners are currently taking full allocation and acknowledged the 10% spodumene/LCE ratio can shift between 5-10%.

Sheorey clarified the scenarios use observed market prices run through their book of business to generate EBITDA ranges.

David acknowledged unusual 2026 FCF from Bayer payment, separation costs ($350M), and $1.5B pension contribution ($290M tax benefit), but core FCF conversion remains at 40-50%.

Judd explained the corn/soy volume mix is a Q1 vs Q2 timing issue, noting favorable soy order book and no red flags on share.

Chuck attributed SG&A jump to variable compensation expenses hitting Q4 against a small revenue quarter. R&D up to 8% of sales as planned. Judd said Conkesta finishing 2025 in mid-single-digit penetration, expects to more than double to mid-teens plus in 2026, going 100% licensing through multipliers.

Robert said Spinosyns approaching $900M revenue with 5% organic growth despite flat market. Used as rotation partner against resistance. Chuck added spinosyns is a microbial that's very difficult to replicate.

Robert said multi-sourcing strategy started years ago ahead of tariffs, impact minimal. David said H2 inventories expected around flat to prior year, maybe down slightly.

Judd confirmed essentially zero US corn hybrid imports, 90%+ production is local. David explained cash flow variability driven by Q4 cash credit mix not known until December.

Luciano confirmed cash outlays run about $500 million above operating cash flow this year, most already behind them, with debt stable in Q3 and down in Q4. Bodine said Faustina's ammonia plant runs full, feeding Florida, with excess sold.

Management clarified ammonia portfolio: ~30% Faustina (varies with turnarounds), up to 80% total below-market including gas-tied contracts, 20% spot exposure. Q4 turnaround at Faustina affected mix. Luciano distinguished marginal sulfur at $1,200/ton and ammonia at ~$800/ton versus portfolio averages, marginal costs driving curtailment decisions as they push margins below variable costs. No good visibility on sulfur quantities trapped behind Strait of Hormuz.

Luciano explained ARO and environmental spending flows entirely through operational cash flows, not CapEx. Spread across accrued liabilities (current ARO portion), net income line (accretion expense offset), and other working capital lines. Complex but entirely within operating section of cash flow statement.

Bodine confirmed 10% tariff on most phosphate imports except Russia (currently exempt but threatened with escalation). Wang added imports down approximately 20% YoY for both P&K. Mosaic's own raw material exposure minimal: sulfur from Gulf (no tariff), Canadian dry sulfur exempt under USMCA, ammonia mostly US-contracted or self-produced, with only a small Trinidad volume subject to 15% tariff.

Bodine stated ammonia is exempt in the US where most supply comes from CF Industries contracts. Own Louisiana production is tariff-free. Less than 20% market exposure to any tariff-affected ammonia. No tariff impacts observed to date.

Ciani attributed the cash flow shortfall to ~$300M impact from production volume misses plus $20M in hurricane water removal costs. Confirmed 2025 expects to cover minimum dividend, CapEx, and generate excess cash.

Both parts answered: Beggs reaffirmed the cash flow target and Knavish corrected the second-half volume assumption to low single digits.

Morales: currency impact less than $0.10 positive YoY in Q1, remaining 3 quarters less than half of that, mostly in Q2, all included in original guide. Knavish on auto OEM pricing: acute and well-known event (Iran war) strengthens starting position for negotiations vs having to demonstrate inflation. Some index contracts will auto-adjust with lag. Normalization by Q1 2027 includes all factors. Aerospace output: incremental from $150M debottlenecking in late 2026-2027, step change from $380M new plant in 2028, additional investments being engineered.

Knavish corrected: refinish decline expected low-to-mid (not high) single digits in H1, with slope continuing toward normalization from Q3 double-digit to Q4 high-single to H1 2026 low-to-mid. PMC business also meaningful contributor. Morales confirmed ~980K shares repurchased in Q4 at ~$102 average.

Knavish confirmed 2025 is peak CapEx, glide path back to 3% of sales through 2026-2027. Pre-bought raw materials for tariff mitigation, expects inventory normalization by year-end. Morales expects operating cash flow to grow faster than EBITDA in future years as working capital normalizes.

Morales confirmed cash from ops tracking ahead of prior year, back-half weighted due to business seasonality. On Performance margins, Knavish acknowledged wanting more drop-through but explained conscious decision to invest in aerospace debottlenecking, PMC feet-on-street, and refinish digital tools for long-term share capture.

Knavish confirmed strong majority is Protective globally. China shipbuilding has been strong; biggest Marine strength is aftermarket dry docks. Morales noted PPG also participates in Korea shipbuilding, providing hedged position if Chinese activity shifts.

Steve said the $290 million of Berry transaction/restructuring costs ($160 million integration, $130 million transaction) will fall materially to roughly $50 million of integration-related costs, a cash tailwind separate from the $500 million working capital recovery, and expects reasonably stable resin cost assumptions with high confidence in recovering the Middle East cash.

Steve explained prior guidance assumed inventory reduction; current guidance maintains volume-level inventory at higher cost. FCF impact depends on supply chain normalization. Wouldn't necessarily assume ongoing headwind, could stabilize or reverse once supply chains normalize.

Steve confirmed non-core at 5% H1 EBIT margins (sub-10% EBITDA), below company average with different growth trajectory. On procurement synergies, PK noted they are more volume-driven than price-driven. In a declining resin price environment, large buyers offering volume are attractive to suppliers needing to fill capacity.

Michael broke down Q1 synergies: $33M EBIT (2/3 G&A, 1/3 procurement across regions) plus $5M financial (interest flexibility). PK clarified Rigid volumes down 1% ex NA Bev, down 2.5% including NA Bev.

Erik candidly acknowledged Q4 Food Ingredients missed expectations but cited strong Q1 2026 start with confidence in low single-digit top-line growth and continued strong EBITDA growth. DeVeau noted favorable tax attributes to minimize leakage on potential sale proceeds.

DeVeau explained emerging market currency headwinds offsetting euro tailwind, with FX about 1% drag on full year but improving in H2. No hedging program in place. Erik confirmed Food Ingredients is more capital intensive, doesn't see it being carved up significantly, views it as stand-alone entity with collaboration continuing.

Erik confirmed they are looking at strategic options for food ingredients but emphasized ongoing transformation progress. More to say toward later 2025 and into 2026.

Koch confirmed Beth Ferreira (ex-ITW) deploying 80/20 across Diversified Industrials. Goal to shift portfolio from 50/50 to 2/3 secular (Healthcare & Water) vs 1/3 diversified.